JP2012505221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505221A5 JP2012505221A5 JP2011531120A JP2011531120A JP2012505221A5 JP 2012505221 A5 JP2012505221 A5 JP 2012505221A5 JP 2011531120 A JP2011531120 A JP 2011531120A JP 2011531120 A JP2011531120 A JP 2011531120A JP 2012505221 A5 JP2012505221 A5 JP 2012505221A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10297408P | 2008-10-06 | 2008-10-06 | |
| US61/102,974 | 2008-10-06 | ||
| PCT/US2009/059730 WO2010042543A2 (en) | 2008-10-06 | 2009-10-06 | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505221A JP2012505221A (ja) | 2012-03-01 |
| JP2012505221A5 true JP2012505221A5 (enExample) | 2012-07-05 |
Family
ID=41472585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531120A Pending JP2012505221A (ja) | 2008-10-06 | 2009-10-06 | 高コレステロール血症および高脂血症ならびにそれらに関連する疾患の予防および処置におけるトル様受容体の阻害剤の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8853177B2 (enExample) |
| EP (2) | EP3087988A3 (enExample) |
| JP (1) | JP2012505221A (enExample) |
| KR (1) | KR20110071108A (enExample) |
| CN (1) | CN102281880A (enExample) |
| AU (1) | AU2009302468A1 (enExample) |
| CA (1) | CA2738816A1 (enExample) |
| MX (1) | MX2011003625A (enExample) |
| WO (1) | WO2010042543A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090082507A (ko) | 2006-11-20 | 2009-07-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 통증 및 소양증 치료용 방법, 조성물 및 키트 |
| WO2010054288A2 (en) * | 2008-11-07 | 2010-05-14 | National Jewish Health | Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs") |
| EP2451974A2 (en) * | 2009-07-08 | 2012-05-16 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
| WO2011006073A1 (en) | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| CN107012149A (zh) | 2010-11-19 | 2017-08-04 | 艾德拉药物股份有限公司 | 调控基于toll‑样受体的免疫应答的免疫调节寡核苷酸(iro)化合物 |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| AU2014205544B2 (en) | 2013-01-08 | 2018-07-12 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| JP6434487B2 (ja) * | 2013-03-15 | 2018-12-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 炎症を伴う疾患の治療のためのデスエチルヒドロキシクロロキン |
| JP6286065B2 (ja) | 2014-12-14 | 2018-02-28 | ヴィア アライアンス セミコンダクター カンパニー リミテッド | アウトオブオーダープロセッサの書き込み結合メモリ領域アクセスに依存するロードリプレイを除外する装置及び方法 |
| KR101745524B1 (ko) | 2015-05-29 | 2017-06-12 | 아주대학교산학협력단 | 신규한 tlr2 길항제 |
| WO2016195194A2 (ko) * | 2015-05-29 | 2016-12-08 | 아주대학교산학협력단 | 신규한 tlr2 길항제 |
| US11021443B2 (en) | 2015-08-03 | 2021-06-01 | President And Fellows Of Harvard College | Charged ion channel blockers and methods for use |
| CN105506119A (zh) * | 2016-01-08 | 2016-04-20 | 张君 | 大鼠网膜脂肪组织炎症通路关键因子表达水平的测定方法 |
| CN105695625B (zh) * | 2016-04-29 | 2021-12-17 | 宁波大学 | 一种用于辅助诊断原发性高血压的检测试剂盒及其应用 |
| EP3468605A4 (en) | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS |
| JP2021502381A (ja) | 2017-11-08 | 2021-01-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ウイルスベクター誘発性炎症反応を阻害するための組成物および方法 |
| US12440536B2 (en) | 2018-05-18 | 2025-10-14 | The University Of Hong Kong | Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof |
| WO2020011869A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting tlr2 |
| CN109251956A (zh) * | 2018-09-18 | 2019-01-22 | 青岛大学 | 糖尿病大鼠胰岛内MyD88 mRNA表达及黄芪的调节作用 |
| CN113811305A (zh) | 2019-03-11 | 2021-12-17 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US11377422B2 (en) | 2019-03-11 | 2022-07-05 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3129089A1 (en) | 2019-03-11 | 2020-09-17 | Bridget Mccarthy Cole | Ester substituted ion channel blockers and methods for use |
| CA3155568A1 (en) | 2019-11-06 | 2021-05-14 | Bridget Mccarthy Cole | Charged ion channel blockers and methods for use |
| AU2020380118B2 (en) | 2019-11-06 | 2026-06-11 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US11332446B2 (en) | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US6426334B1 (en) * | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| DE60017259T2 (de) * | 1999-08-13 | 2005-12-08 | Hybridon, Inc., Cambridge | Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden |
| US6899891B2 (en) * | 1999-12-16 | 2005-05-31 | Harry J. Siskind | Nutritional composition, methods of producing said composition and methods of using said composition |
| WO2001055370A2 (en) * | 2000-01-26 | 2001-08-02 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| AU2001257366B2 (en) | 2000-05-01 | 2006-03-16 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7105495B2 (en) * | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| WO2003035836A2 (en) * | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| EP1495756A4 (en) * | 2002-04-08 | 2009-10-28 | Takeda Pharmaceutical | THERAPEUTIC AGENT FOR SEVERE SEPTIC STATE PREVENTION |
| SE0201701D0 (sv) | 2002-06-05 | 2002-06-05 | Gotovax Ab | Treatment of epithelial tumors and infections |
| WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| EP1393745A1 (en) | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
| WO2004094671A2 (en) | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| MXPA06000619A (es) * | 2003-07-15 | 2006-04-11 | Hybridon Inc | Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion. |
| JP2007514648A (ja) * | 2003-10-24 | 2007-06-07 | エーザイ株式会社 | Ｔｏｌｌ−ｌｉｋｅｒｅｃｅｐｔｏｒ２に関連する疾患及び状態を治療するための化合物及び方法 |
| US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2005117975A2 (en) * | 2004-05-28 | 2005-12-15 | Cedars-Sinai Medical Center | Methods for treating vascular disease |
| PL1794174T3 (pl) * | 2004-09-01 | 2012-11-30 | Dynavax Tech Corp | Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności |
| EP1819364A4 (en) | 2004-12-08 | 2010-12-29 | 3M Innovative Properties Co | COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS |
| AU2005316503A1 (en) * | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| US20060257411A1 (en) * | 2005-05-06 | 2006-11-16 | Bruce Beutler | Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway |
| WO2007038720A2 (en) | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| ES2544877T3 (es) * | 2005-10-12 | 2015-09-04 | Idera Pharmaceuticals | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| US8399423B2 (en) * | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8383598B2 (en) * | 2005-10-12 | 2013-02-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8426375B2 (en) * | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8377898B2 (en) * | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| JP2010536787A (ja) * | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様受容体モジュレータ |
| EP2209896B1 (en) * | 2007-10-26 | 2017-03-01 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| WO2009058361A1 (en) * | 2007-10-31 | 2009-05-07 | Dynavax Technologies Corp. | Inhibition of type i ifn production |
| WO2009154609A1 (en) * | 2008-06-17 | 2009-12-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| US11114308B2 (en) | 2018-09-25 | 2021-09-07 | International Business Machines Corporation | Controlling of height of high-density interconnection structure on substrate |
| US11116008B2 (en) | 2018-11-02 | 2021-09-07 | Samsung Electronics Co., Ltd. | Method and device for radio resource allocation in wireless communication system |
| TWI711225B (zh) | 2019-07-01 | 2020-11-21 | 唐虞企業股份有限公司 | 連接器總成 |
-
2009
- 2009-10-06 EP EP16172784.7A patent/EP3087988A3/en not_active Withdrawn
- 2009-10-06 WO PCT/US2009/059730 patent/WO2010042543A2/en not_active Ceased
- 2009-10-06 AU AU2009302468A patent/AU2009302468A1/en not_active Abandoned
- 2009-10-06 US US12/574,576 patent/US8853177B2/en active Active
- 2009-10-06 EP EP09740570A patent/EP2349271A2/en not_active Withdrawn
- 2009-10-06 JP JP2011531120A patent/JP2012505221A/ja active Pending
- 2009-10-06 CA CA2738816A patent/CA2738816A1/en not_active Abandoned
- 2009-10-06 MX MX2011003625A patent/MX2011003625A/es unknown
- 2009-10-06 KR KR1020117010318A patent/KR20110071108A/ko not_active Withdrawn
- 2009-10-06 CN CN2009801396287A patent/CN102281880A/zh active Pending